Newly identified mechanism of p53-induced cell death could aid cancer therapy

Research led by St. Jude Children’s Research Hospital reveals how the tumor suppressor protein p53 works in the cytoplasm to trigger death via apoptosis and identifies a potential cancer treatment strategy.

Memphis, Tennessee, July 30, 2015

Richard Kriwacki and Ariele Folis

Richard Kriwacki, Ph.D. (left), discusses research and data with Ariele Folis, Ph.D. (right)

Researchers have identified a new mechanism that the tumor suppressor protein p53 uses to trigger cell death via apoptosis and have shown how the process could be harnessed to kill cancer cells. St. Jude Children’s Research Hospital scientists led the study, which appears today in the scientific journal Molecular Cell.

Investigators showed how p53 acts in the cytoplasm to trigger cell death by binding to and activating a protein called BAX. Using the tools of structural biology, researchers discovered the process involves a shape change in one of p53’s amino acids that serves as the “switch” to activate BAX and trigger the suicide or apoptotic pathway. The scientists also identified the enzyme in the cytoplasm that promotes the change that controls the “switch.”

P53 is widely known for its role in cancer prevention. The protein, or the pathway that controls p53’s function, are inactivated in most cancers. P53 is best known for working in the cell nucleus as a transcription factor, regulating apoptosis by controlling expression of specific genes, including those involved in apoptosis.

P53 also exists in the cytoplasm. Previous research by St. Jude investigators and others suggested that p53 works there through the BAX protein to trigger programmed cell death or apoptosis. Until now, however, the mechanism involved was unknown.

“These results expand our understanding of the different ways p53 modulates cell behavior. The findings also raise the possibility of killing tumor cells using small molecules to trigger BAX-dependent apoptosis,” said Richard Kriwacki, Ph.D., a member of the St. Jude Department of Structural Biology. Kriwacki and Douglas Green, Ph.D., chair of the St. Jude Department of Immunology, are co-corresponding authors.

The findings represent more than a decade of research by the Green and Kriwacki laboratories into how p53 acts in the cytoplasm to modulate apoptosis.

“The p53 protein is almost universally regarded as working in the nucleus and was thought to have no function in other parts of the cell,” Green said.  “Our study provides the first biophysical insights into how p53 can have another function, one with important consequences for cancer.”

Like up to half of all proteins, p53 includes both structured and disordered regions. Investigators showed that both play a role in BAX activation in the cytoplasm.

The process starts when a structured region of p53 region known as the DNA-binding domain binds to BAX. That sets the stage for the unstructured region of p53 to form a second bond, which activates BAX and triggers apoptosis. “There were no previous reports of this disordered region of p53 binding to BAX, so the finding that this region was the key to BAX activation was a total surprise,” Kriwacki said.  A “disordered region” of a protein is a segment that does not adopt a single shape but remains flexible and constantly switches between different shapes until it encounters a partner like BAX.

New p53 Mechanism Identified for Triggering Apoptosis

The disordered p53 segment included the amino acid proline, which can change between two shapes, particularly in the presence of the enzyme Pin1. Using a structural technique called NMR spectroscopy researchers showed that the proline shape change promotes the p53 binding and activation of BAX.

St. Jude researchers hope insights from this study will help them develop small molecules that can mimic the shape “switch” and trigger apoptosis in tumor cells. “That’s a future direction of this research,” Kriwacki said.

The first author is Ariele Viacava Follis, a postdoctoral fellow in Kriwacki’s laboratory. The other authors are Fabien Llambi, St. Jude; Parker Merritt, formerly of St. Jude; and Jerry Chipuk, of the Icahn School of Medicine at Mount Sinai, New York.

The research was funded in part by grants (CA082491, GM083159, GM52735, GM96208, CA157740, CA21765) from the National Institutes of Health; the American Cancer Society Research Scholar Award to Chipuk; and ALSAC.

Read the Research Highlight.

St. Jude Children’s Research Hospital

St. Jude Children’s Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20 percent to 80 percent since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow the hospital on Twitter and Instagram at @stjuderesearch.